ETF v praxi
HEAL (MSCI World Health Care): ETF Review — Holdings, TER and Who It's For
Key takeaways
- HEAL tracks the MSCI World Health Care Index — over 150 healthcare companies from developed global markets.
- Healthcare is a defensive sector: people buy medicines even in a recession, which reduces portfolio cyclicality.
- The approximate TER is around 0.25% per year; always verify the exact figure on justETF.
- Specific risks: regulatory interventions, failed clinical trials, patent cliffs at major pharma companies.
- Suitable as a defensive satellite — reduces overall portfolio cyclicality without leaving the equity class.
HEAL is a sector ETF that bets on one of the few industries not fully dependent on the economic cycle — healthcare. The iShares fund tracks the MSCI World Health Care Index and covers over 150 companies: from pharmaceutical giants (Eli Lilly, Johnson & Johnson, Novo Nordisk) through medical equipment manufacturers to managed care insurers. Healthcare is classically defensive, but with its own specific risks.
What the fund contains and how it is structured
The MSCI World Health Care Index is global but strongly dominated by the US (typically 60–70%). The remainder consists of European pharmaceutical companies (Roche, Novartis, AstraZeneca) and Japanese healthcare companies. Sub-sectors include pharmaceuticals, biotechnology, medical devices, distribution and insurance. Biotechnology is the more volatile part — failure of a clinical trial can cause a sharp drop in a specific stock.
Costs and structure
The approximate TER is around 0.25% per year — slightly above broad market but still acceptable for a sector fund. HEAL is an Irish accumulating UCITS ETF with physical replication. It trades in USD and euros. Dividend yields from healthcare companies are generally solid, but the accumulating structure reinvests them automatically.
Defensive properties — what this means in practice
- People buy medicines and healthcare regardless of recession — demand is relatively stable.
- In historical downturns (2008, 2020), healthcare fell less than the overall market.
- Ageing populations in the developed world provide a structural tailwind for the sector.
- Lower correlation with the economic cycle reduces portfolio volatility.
Specific healthcare risks
Regulatory risk is key — changes in the US healthcare insurance system or pressure on drug prices can dramatically affect pharmaceutical returns. A patent cliff occurs when large companies' blockbuster patents expire and generics erode margins. The biotech portion is particularly volatile. For a general risk analysis, read the article on risk and how to measure it; for broader context, the ETF overview.
FAQ
Is HEAL truly defensive, or is that a myth?
Healthcare is relatively defensive compared to cyclical sectors — it falls less in recessions. But it is not risk-free: regulatory shocks or failures of major clinical trials can cause significant drops. Defensive does not mean safe.
What share of a portfolio should be in HEAL?
Typically 5–15% as a satellite alongside a global core ETF. More would mean too great a sector concentration. It depends on your thesis about the demographic ageing trend and tolerance for regulatory risk.
Is Novo Nordisk included in HEAL?
Yes, Novo Nordisk — the Danish maker of diabetes and obesity drugs (Ozempic, Wegovy) — is part of MSCI World Health Care and is one of its more significant positions. The weight changes with the company's market capitalisation.